Fulcrum Therapeutics, Inc. (FULC) Dividend History

Company News

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted stock options to a new employee as an inducement to join the company.

  GlobeNewswire Inc.
• Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

  Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will release its third quarter 2024 financial results and host a conference call and webcast on November 13, 2024.

  GlobeNewswire Inc.
• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted stock options to two new employees as an inducement to join the company.

  GlobeNewswire Inc.
• BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

  Biohaven's pipeline candidate, troriluzole, met the primary endpoint in a pivotal study for the treatment of spinocerebellar ataxia, a rare neurological disease. The study showed a 50-70% delay in disease progression compared to untreated patients.

  Benzinga

  Featured Companies: ANIP BHVN KRYS
• FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

  Fulcrum Therapeutics, Inc. announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD did not achieve its primary endpoint, causing a significant drop in the company's stock price.

  GlobeNewswire Inc.